Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Quoin Pharmaceuticals Ltd.

NASDAQ: QNRX · Life Sciences · 7 alerts · CIK 1671502

Share price
$3.56Close, Nov 16
Market cap
$250M
Shares outstanding
70.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Quoin Pharmaceuticals Ltd. filings on SEC EDGAR ↗

5:19 PM ET 8-K
Financial Results

Quoin Pharmaceuticals Financial Results

Quoin Pharmaceuticals reported third quarter 2026 financial results and provided a corporate update, including positive interim Phase 2/3 data for QRX003 in Netherton Syndrome. The company also highlighted a private placement financing of up to $50.0 million to fund the completion of QRX003 development. Topline data for the Netherton Syndrome study is expected in Q2 2027.

“The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth. Interim clinical results from our Phase 2/3 study of QRX003 in Netherton Syndrome demonstrated statistical significance for the primary and key secondary endpoints, representing what we believe is the first ever overall positive data set published for this disease.”

Dr. Michael Myers, Chief Executive Officer and Co-Founder

“Our priorities for the coming months are very clear. We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027.”

Dr. Michael Myers, Chief Executive Officer and Co-Founder
4:19 PM ET 10-Q
Financial Results

Quoin Pharmaceuticals Q3 2026 Results: Net Loss of $4.87M, Loss Widens

Quoin Pharmaceuticals reported a net loss of $15.2 million for the nine months ended September 30, 2026, compared to $11.5 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through equity issuances, ending the period with $34.4 million in total current assets and $28.7 million in shareholders' equity.

Key figure
Net loss $4.87M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.